BioSpace News Archive

OpGen, Inc. reported that its Principal Scientist Dr. Matthias Klein has presented results from the clinical trial for its Unyvero Urinary Tract Infection Panel during ASM Microbe’s In Depth Symposium session ‘The Year in Clinical Microbiology’ on June 17th in Houston, TX.

CureVac N.V. today announced the appointment of Michael Brosnan as an independent director to the company’s Supervisory Board.

Precigen, Inc. today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the first-in-class investigational PRGN-2012 AdenoVerse immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP).

HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’) announced today that the first patient has been enrolled in the Olive trial, a randomized, double-blind, placebo-controlled trial in more than 300 patients with Major Depressive Disorder (MDD) conducted in eight countries in Europe.

Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, today announced a multi-level collaboration agreement with the Molecular Biology Institute of Paraná (IBMP) in Brazil.

aTyr Pharma, Inc. announced that the company will present on its lead therapeutic candidate, efzofitimod, at the World Association for Sarcoidosis and Other Granulomatous Disorders Conference, which is scheduled to take place June 19 – 21, 2023, in Stockholm, Sweden.

STERIS plc announced that the Company has signed a definitive agreement to purchase the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company for $540 million.

LifeMD, Inc., a leading provider of virtual primary care services, announced the appointment of William J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation to its Board of Directors.

Nuvectis Pharma, Inc. announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of the 2023 Russell indexes reconstitution, according to a preliminary list of additions posted May 19, and effective upon the U.S. market close on June 23, 2023.

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutic Pipeline Program.